Search

Predictors of IOP reduction after SLT

The aim of this study was to identify predictors of intraocular pressure reduction following selective laser trabeculoplasty (SLT) in patients with primary open-angle glaucoma, who are already taking maximally tolerated IOP-lowering medication and need further IOP reduction. In this prospective...

Understanding retinal ciliopathy through Bardet-Biedl syndrome

This is a review article looking at up-to-date understanding and ongoing research in retinal ciliopathies. Syndromic ciliopathies consist of a group of disorders caused by ciliary dysfunction or abnormal ciliogenesis. These disorders have multiorgan involvement in addition to retinal degeneration...

Corectopia grading

The authors present a novel corectopia classification system using 28 eyes of 28 patients with or without corectopia. The grading and classification system for corectopia was as follows: (i) Direction of decentration: superior (DecS), superonasal (DecSN), nasal (DecN), inferonasal (DecIN),...

Non-contact-lens-associated acanthamoeba keratitis

This retrospective study was done to study the clinical presentation and microbiological results of non-contact-lens-related acanthamoeba keratitis (AK). One hundred and ninety-four patients with microbiological / histopathological diagnosis of AK over four years were included. All patients had corneal scrapings...

Corneal crosslinking in pellucid marginal degeneration

Fourteen studies were included in this first review examining the use of corneal-crosslinking (CXL) to treat pellucid marginal degeneration (PMD). PMD is a bilateral, non-inflammatory corneal thinning disorder characterised by inferior peripheral corneal thinning 1-3mm from the limbus in the...

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...

Progression of macular atrophy on long-term anti-VEGF therapy for AMD

This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...

OCT prognostic factors in AMD patients with peripapillary choroidal neovascularisation

In this retrospective study the authors aimed to investigate the correlation between optical coherence tomography (OCT) findings and visual acuity outcomes after treatment with intravitreal bevacizumab (IVB) injections for age-related macular degeneration (AMD) patients with peripapillary choroidal neovascularisation (PPCNV). Data...

Atrophy and anti-VEGF

The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...